Selective serotonin reuptake inhibitors in intellectual disability

Mental Retardation and Developmental Disabilities Research Reviews

Volumn 5, Issue 4, 1999, Pages 264-269

  Racusin, Robert ^a,b   Kovner Kline, Kathleen ^a   King, Bryan H ^a  

^a DARTMOUTH MEDICAL SCHOOL   (United States)

^b DARTMOUTH HITCHCOCK MEDICAL CENTER   (United States)

Author keywords

Intellectual disability; Pharmacotherapy; Selective serotonin reuptake inhibitors

Indexed keywords

ANTICOAGULANT AGENT; ANTICONVULSIVE AGENT; CYTOCHROME P450; CYTOCHROME P450 INHIBITOR; SEROTONIN; SEROTONIN 1A RECEPTOR; SEROTONIN 2A RECEPTOR; SEROTONIN UPTAKE INHIBITOR;

AGITATION; ANXIETY; BRAIN DEVELOPMENT; DEPRESSION; DRUG DISTRIBUTION; DRUG ELIMINATION; DRUG HALF LIFE; DRUG METABOLISM; DRUG OVERDOSE; DRUG WITHDRAWAL; EXTRAPYRAMIDAL SYMPTOM; GASTROINTESTINAL SYMPTOM; HUMAN; HYPOMANIA; INTELLECTUAL IMPAIRMENT; MENTAL DEFICIENCY; NEUROTOXICITY; PHARMACODYNAMICS; PRIORITY JOURNAL; REVIEW; SEROTONINERGIC SYSTEM; SLEEP DISORDER;

EID: 0033386590     PISSN: 10804013     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1098-2779(1999)5:4<264::AID-MRDD3>3.0.CO;2-K     Document Type: Review

References (69)

1. Abramson RK, Wright HH, Carpenter R, et al. 1989. Elevated blood serotonin in autistic probands and their first-degree relatives. J Autism Dev Disord 19:397-407.
2. Akefeldt A, Ekman R, Gillberg C, et al. 1998. Cerebrospinal fluid monoamines in Prader-Willi syndrome. Biol Psychiatry 44:1321-1328.
3. Awad GA. 1996. The use of selective serotonin reuptake inhibitors in young children with pervasive developmental disorders: some clinical observations. Can J Psychiatry 41:361-366.
4. Barak Y, Ring A, Levy D, et al. 1995. Disabling compulsions in 11 mentally retarded adults: an open trial of clomipramine SR. J Clin Psychiatry 56:459-461.
5. Birmaher B, Yelovich AK, Renaud J. 1998. Pharmacologic treatment for children and adolescents with anxiety disorders. Pediatr Clin North Am 45:1187-1204.
6. Borella A, Bindra M, Whitaker-Azmitia PM. 1997. Role of the 5-HT1A receptor in development of the neonatal rat brain: preliminary behavioral studies. Neuropharmacology 36:445-450.
7. Branford D, Bhaumik S, Naik B. 1998. Selective serotonin re-uptake inhibitors for the treatment of perseverative and maladaptive behaviours of people with intellectual disability. J Intellect Disabil Res 42:301-306.
8. Buitelaar JK. 1993. Self-injurious behaviour in retarded children: clinical phenomena and biological mechanisms. Acta Paedopsychiatr 56:105-111.
9. Campbell JJ 3rd, Duffy JD. 1995. Sertraline treatment of aggression in a developmentally disabled patient [letter]. J Clin Psychiatry 56:123-124.
10. Coleman M. 1973. Serotonin and central nervous system syndromes of childhood: a review. J Autism Child Schizophrenia 3:27-35.
11. Cook EH, Rowlett R, Jaselskis C, et al. 1992. Fluoxetine treatment of children and adults with autistic disorder and mental retardation. J Am Acad Child Adolesc Psychiatry 31:739-745.
12. Cookson J, Duffet R. 1998. Fluoxetine: therapeutic and undesirable effects. Hosp Med 59:622-626.
13. Davanzo PA, Belin TR, Widawski MH, et al. 1998. Paroxetine treatment of aggression and self-injury in persons with mental retardation. Am J Ment Retard 102:427-437.
14. del Olmo E, Lopez-Gimenez JF, Vilaro MT, et al. 1998. Early localization of mRNA coding for 5-HT1A receptors in human brain during development. Brain Res Mol Brain Res 60:123-26.
15. DeLong GR, Teague LA, Kamran MM. 1998. Effects of fluoxetine treatment in young children with idiopathic autism. Dev Med Child Neurol 40:551-562.
16. DeVane C.L. 1992. Pharmacokinetics of the selective serotonin reuptake inhibitors. J Clin Psychiatry 53(suppl): 13-20.
17. DeVane CL. 1994. Pharmacogenetics and drug metabolism of newer antidepressant agents. J Clin Psychiatry 55(suppl):38-47.
18. Emslie GJ, Weinberg WA, Mayes TL. 1998. Treatment of children with antidepressants: focus on selective serotonin reuptake inhibitors. Depression Anxiety 8(suppl 1):13-17.
19. Emslie GJ, Walkup JT, Pliszka SR, et al. 1999. Nontricyclic antidepressants: current trends in children and adolescents. J Am Acad Child Adolesc Psychiatry 38:517-528.
20. Ereshefsky L. 1998. Antidepressant pharmacodynamics, pharmacokinetics, and drug interactions. Geriatrics 53(suppl 4):S22-S33.
21. Fatemi SH, Realmuto GM, Khan L, et al. 1998. Fluoxetine in treatment of adolescent patients with autism: a longitudinal open trial. J Autism Dev Disord 28:303-307.
22. Gorio A, Germani E, Mantegazza P, et al. 1992. Perinatal exposure to ethanol affects postnatal degeneration and regeneration of serotoninergic pathways in the spinal cord. Drugs Exp Clin Res 18:461-464.
23. Greenberg A, Coleman M. 1973. Depressed whole blood serotonin levels associated with behavioral abnormalities in the de Lange syndrome. Pediatrics 52:720-724.
24. Hanley HG, Stahl SM, Freedman DX. 1977. Hyperserotonemia and amine metabolites in autistic and retarded children. Arch Gen Psychiatry 34:521-531.
25. Hellings JA, Kelley LA, Gabrielli WF, et al. 1996. Sertraline response in adults with mental retardation and autistic disorder. J Clin Psychiatry 57:333-336.
26. Ho HH, Lockitch G, Eaves L, et al. 1986. Blood serotonin concentrations and fenfluramine therapy in autistic children. J Pediatr 108:465-469.
27. Hoehn-Saric R, Lipsey JR, McLeod DR. 1990. Apathy and indifference in patients on fluvoxamine and fluoxetine. J Clin Psychopharmacol 10:343-345.
28. King BH. 1993. Self-injury by people with mental retardation: a compulsive behavior hypothesis. Am J Ment Retard 98:93-112.
29. Koski KG, Lanoue L, Young SN. 1993. Restriction of maternal dietary carbohydrate decreases fetal brain indoles and glycogen in rats. J Nutrition 123:42-51.
30. Koski KG, Lanoue L, Young SN. 1995. Maternal dietary carbohydrate restriction influences the developmental profile of postnatal rat brain indoleamine metabolism. Biol Neonate 67: 122-131.
31. Labellarte MJ, Walkup JT, Riddle MA. 1998. The new antidepressants: selective serotonin reuptake inhibitors. Pediatr Clin North Am 45:1137-1155.
32. Leonard BE. 1996. The comparative pharmacological properties of selective serotonin inhibitors in animals. In: Selective serotonin reuptake inhibitors. 2nd edition. West Sussex, England: Wiley. p 35-62.
33. Leonard HL, March J, Rickler KC, et al. 1997. Pharmacology of the selective serotonin reuptake inhibitors in children and adolescents. J Am Acad Child Adolesc Psychiatry 36:725-736.
34. Lesch KP, Mossner R. 1998. Genetically driven variation in serotonin uptake: is there a link to affective spectrum, neurodevelopmental, and neurodegenerative disorders? Biol Psychiatry 44:179-192.
35. Lewis MH, Bodfish JW, Powell SB, et al. 1995. Clomipramine treatment for stereotype and related repetitive movement disorders associated with mental retardation. Am J Ment Retard 100:299-312.
36. Lewis MH, Bodfish JW, Powell SB, et al. 1996. Clomipramine treatment for self-injurious behavior of individuals with mental retardation: a double-blind comparison with placebo. Am J Ment Retard 100:654-665.
37. Marazziti D, Palego L, Silvestri S, et al. 1996. Platelet abnormalities in aggressive subjects with mental deficiency. J Psychiatry Neurosci 21:109-113.
38. Markowitz PI. 1992. Effect of fluoxetine on self-injurious behavior in the developmentally disabled: a preliminary study. J Clin Psychopharmacol 12:27-31.
39. Mazer C, Muneyyirci J, Taheny K, et al. 1997. Serotonin depletion during synaptogenesis leads to decreased synaptic density and learning deficits in the adult rat: a possible model of neurodevelopmental disorders with cognitive deficits. Brain Res 760:68-73.
40. McCoy EE, Rostafinsky MJ, Fishburn C. 1968. The concentration of serotonin by platelets in Down's Syndrome. J Ment Def Res 12: 18-21.
41. McDougle CJ, Naylor ST, Cohen DJ, et al. 1996. A double-blind, placebo-controlled study of fluvoxamine in adults with autistic disorder. Arch Gen Psychiatry 46:213-221.
42. Nalini K, Aroor AR, Rao A. 1988. Urinary levels of biogenic amine metabolites in mentally retarded children. J Ment Defic Res 32:419-424.
43. Nomura Y, Segawa M, Higurashi M. 1985. Rett syndrome - an early catecholamine and indolamine deficient disorder? Brain Dev 7:334-341, 1985.
44. Oikawa K, Deonauth J, Breidbart S. 1978. Mental retardation and elevated serotonin levels in adults. Life Sci 23:45-47.
45. Pare CM. 1968. 5-hydroxyindoles in phenylketonuric and nonphenylketonuric mental defectives. Advances in Pharmacology 6:159-65.
46. Partington MW, Tu JB, Wong CY. 1973. Blood serotonin levels in severe mental retardation. Dev Med Child Neurol 15:616-627.
47. Peters DA. 1990. Maternal stress increases fetal brain and neonatal cerebral cortex 5-hydroxytryptamine synthesis in rats: a possible mechanism by which stress influences brain development. Pharmacol Biochem Behav 35:943-947.
48. Potenza MN, McDougle CJ. 1997. The role of serotonin in autism-spectrum disorders. CNS Spectrums 2:25-42.
49. Preskorn S. 1993. Pharmacokinetics of antidepressants: how and why they are relevant to treatment. J Clin Psychiatry 54(suppl):14-34.
50. Preskorn S. 1994. Targeted pharmacotherapy in depression management: comparative pharmacokinetics of fluoxetine, paroxetine and sertraline. Int Clin Psychopharmacol 9(suppl 3): 13-19.
51. Ricketts RW, Goza AB, Ellis CR, et al. 1993. Fluoxetine treatment of severe self-injury in young adults with mental retardation. J Am Acad Child Adolesc Psychiatry 32:865-869.
52. Riddle MA, Brown N, Dzubinski D, et al. 1989. Fluoxetine overdose in an adolescent. J Am Acad Child Adolesc Psychiatry 23:587-588.
53. Riddle MA, King RA, Hardin MT, et al. 1990. Behavioral side effects of fluoxetine in children and adolescents. J Child Adolesc Psychopharmacol 1:193-198.
54. Riederer P, Weiser M, Wichart I, et al. 1986. Preliminary brain autopsy findings in progredient Rett syndrome. Am J Med Genet Suppl 1:305-315.
55. Ritvo ER. 1977. Biochemical studies of children with the syndromes of autism, childhood schizophrenia and related developmental disabilities: a review. J Child Psychol Psychiatry 18:373-379.
56. Sanchez C, Meier E. 1997. Behavioral profiles of SSRIs in animal models of depression, anxiety and aggression. Are they all alike? Psychopharmacology 129:197-205.
57. Singh VK, Singh EA, Warren RP. 1997. Hyperserotoninemia and serotonin receptor antibodies in children with autism but not mental retardation. Biol Psychiatry 41:753-755.
58. Sternbach H. 1991. The serotonin syndrome. Am J Psychiatry 148:705-713.
59. Stokes PE. 1993. Fluoxetine: a five year review. Clin Ther 15:216-243.
60. Todd RD. 1992. Neural development is regulated by classical neurotransmitters: dopamine D2 receptor stimulation enhances neurite outgrowth. Biol Psychiatry 31:794-807.
61. Troisi A, Vicario E, Nuccetelli F, et al. 1995. Effects of fluoxetine on aggressive behavior of adult inpatients with mental retardation and epilepsy. Pharmacopsychiatry 28:73-76.
62. Tu J, Partington MW. 1972. 5-Hydroxyindole levels in the blood and CSF in Down's syndrome, phenylketonuria and severe mental retardation. Dev Med Child Neurol 14:457-466.
63. Tukiainen E, Tuomisto J, Westermarck T, et al. 1980. Nature of lowered 5-hydroxytryptamine uptake by blood platelets of patients with Down's syndrome. Acta Pharmacol Toxicol 47:365-370.
64. Verhoeven WM, Tuinier S. 1996. The effect of buspirone on challenging behaviour in mentally retarded patients: an open prospective multiple-case study. J Intellect Disabil Res 40:502-508.
65. Verhoeven WM, Tuinier S, van den Berg YW. et al. 1999. Stress and self-injurious behavior; hormonal and serotonergic parameters in mentally retarded subjects. Pharmacopsychiatry 32:13-20.
66. Wegerer V, Moll GH, Bagli M, et al. 1999. Persistently increased density of serotonin transporters in the frontal cortex of rats treated with fluoxetine during early juvenile life. J Child Adolesc Psychopharmacol 9: 13-24.
67. Wiener K, Lamberti JS. 1993. Sertraline and mental retardation with obsessive-compulsive disorder [letter]. Am J Psychiatry 150:1270.
68. Woolley DW, Van der Hoeven T. 1965. Serotonin deficiency in infancy as a cause of a mental defect in experimental phenylketonuria. Int J Neuropsych 1:529-44.
69. Zajecka J, Tracy KA, Mitchell S. 1997. Discontinuation symptoms after treatment with serotonin reuptake inhibitors: a literature review. J Clin Psychiatry 58:291-297.